Effect of Sarcopenia in Stroke Patients

Study Overview
=================
Brief Summary
-----------------
Primary research purpose: -Prospective study to screen post stroke patients with sarcopenia and evaluate its effect on recovery Secondary research purpose: To determine the degree of sarcopenia and correlation with poor functional prognosis of stroke in the stroke patient group. To determine the degree of sarcopenia and correlation with dixon MRI of thigh muscle To evaluate surface EMG (SEMG)-based signals and correlation with sarcopenia To determine the degree of sarcopenia and correlation with brain morphometric changes

Detailed Description
-----------------
Patients with first-ever stroke will be enrolled and assessed for sarcopenia. The evaluation parameters will include standard sarcopenia parameters and also SEMG-based signals and imaging studies.

Official Title
-----------------
Effect of Sarcopenia in Stroke Patients

Conditions
-----------------
Stroke, Sarcopenia

Intervention / Treatment
-----------------
* Diagnostic Test: DEXA Scan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients 65 years of age or older, stroke patients with first onset within 4 weeks Exclusion Criteria: Patients who have not been evaluated for sarcopenia Patients with neuromuscular diseases other than stroke that may affect gait function Patients unable to conduct clinical trials according to instructions Patients with uncontrolled medical/surgical disease Patients with metal substances in the body such as cardiac pacemakers, cochlear implants, etc. Patients who have difficulty collecting blood Patients who are difficult to follow up after 6 months of onset due to moving to another area Patients who have Parkinson's disease, dementia, or have a history of neuromuscular diseases such as Guillain-Barré syndrome or myasthenia gravis

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Stroke patients with sarcopenia<br>Group will be stratified according to gender | Diagnostic Test: DEXA Scan<br>* Fu of diagnostic tests<br>* Other names: Serum biomarkers, SEMG signals and MRI changes;|
| Stroke patients without sarcopenia<br>Group will be stratified according to gender | Diagnostic Test: DEXA Scan<br>* Fu of diagnostic tests<br>* Other names: Serum biomarkers, SEMG signals and MRI changes;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of Modified Rankin Scale | Functional Disability -> The scale runs from 0-6, running from perfect health without symptoms(0) to death(6). | 6 months from the first onset of the stroke | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hand grip strength | Grip strength: Grip strength will be measured using a dynamometer | within 4 weeks, 4 weeks, 8 weeks, 6 months from the first onset of the stroke | 
| quadriceps muscle strength | Lower extremity strength assessment:change in isometric quadriceps muscle strength (kg) from initial evaluation to the final evaluation | within 4 weeks, 4 weeks, 8 weeks, 6 months from the first onset of the stroke | 
| Fugl-Meyer motor scale | Motor function assessment : Fugl-Meyer motor scale from initial evaluation to the final evaluation (Upper Extremity maximum score = 66; Lower Extremity maximum score = 34, Higher score means better outcome) | within 4 weeks, 4 weeks, 8 weeks, 6 months from the first onset of the stroke | 
| Functional Ambulation Category | Gait function assessment : Functional Ambulation Category from initial evaluation to the final evaluation (Minimum 0, Maximum 5; Higher score means better outcome) | within 4 weeks, 4 weeks, 8 weeks, 6 months from the first onset of the stroke | 
| Berg balance scale | Balance function: change in Berg balance scale from initial evaluation to the final evaluation (Minimum score 0, Maximum score 56, Higher score means better outcome) | within 4 weeks, 4 weeks, 8 weeks, 6 months from the first onset of the stroke | 
| Brain MRI | Brain atrophy : change in the Global cortical atrophy scale(0-3) of the cerebral cortex from initial evaluation to the final evaluation | within 4 weeks and 6 months from the first onset of the stroke | 
| Thigh Dixon MRI | Muscle quality : muscle circumference measured by the thigh MRI from initial evaluation to the final evaluation | within 4 weeks and 6 months from the first onset of the stroke | 
| Muscle ultrasonography | muscle thickness(cm) measured by the ultrasound of the quadriceps muscle from initial evaluation to the final evaluation | within 4 weeks and 6 months from the first onset of the stroke | 
| serum biomarkers for sarcopenia | BNDF, IL-6 | within 4 weeks from the first onset of the stroke | 
| Digitalized SEMG signals | state of the art EMG signals will be collected to assess muscle quality changes after stroke | within 4 weeks, 4 weeks, 8 weeks, 6 months from the first onset of the stroke |